{"id":"r2-mant","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3929490","moleculeType":"Small molecule","molecularWeight":"287.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"R2-MANT appears to be an investigational combination or novel formulation approach for mantle cell lymphoma (MCL), likely leveraging rituximab (anti-CD20) as a backbone. The specific mechanistic innovation of the 'MANT' component is not publicly well-characterized in standard pharmaceutical databases, suggesting it may be a proprietary or recently disclosed regimen by Fondazione Italiana Linfomi.","oneSentence":"R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:04.648Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rituximab and Lenalidomide (R2)"],"phase":"phase_3","status":"active","brandName":"R2-MANT","genericName":"R2-MANT","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R2-MANT is a mantle cell lymphoma-directed immunotherapy combining rituximab with a novel antitumor mechanism in phase 3 development. Used for Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}